Status:
COMPLETED
PF-04191834 Single Dose Bronchodilatory Study In Asthma.
Lead Sponsor:
Pfizer
Conditions:
Asthma
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
Study to determine the bronchodilatory effects of PF-04191834 compared with zileuton in patients with asthma
Eligibility Criteria
Inclusion
- Persistent mild/moderate asthma for at least 6 months.
- Reduced lung function
- Reversible airway obstruction
Exclusion
- Pregnant/nursing females.
- Liver function tests greater than upper limit of normal (ULN)
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00723021
Start Date
July 1 2008
End Date
July 1 2009
Last Update
February 1 2013
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Baltimore, Maryland, United States, 21225
2
Pfizer Investigational Site
North Dartmouth, Massachusetts, United States, 02747
3
Pfizer Investigational Site
Kalamazoo, Michigan, United States, 49007
4
Pfizer Investigational Site
Omaha, Nebraska, United States, 68131